Within the dapagliflozin groups , dose-related reductions in 24-h glucose , glycemic variability , and insulin dose were suggested , which provide hope that SGLT2 inhibition may prove in larger randomized controlled trials to be efficacious in reducing hyperglycemia in type 1 diabetes .